索拉非尼治疗的肝细胞癌患者银屑病缓解
Remission of Psoriasis in a Patient with Hepatocellular Carcinoma Treated with Sorafenib.
作者信息
Antoniou Efstathios A, Koutsounas Ioannis, Damaskos Christos, Koutsounas Sotiris
机构信息
Second Department of Propedeutic Surgery, "Laiko" General Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Academic Department of Gastroenterology, Ethnikon and Kapodistriakon University, School of Medical Sciences, Laikon General Hospital, Athens, Greece.
出版信息
In Vivo. 2016;30(5):677-80.
BACKGROUND
Psoriasis is a chronic, immune-mediated and angiogenesis-dependent disease. Activated keratinocytes in psoriatic lesions produce pro-angiogenic cytokines, including vascular endothelial growth factor (VEGF), which binds to vascular endothelial growth factor receptor (VEGFR) and promotes cell proliferation and angiogenesis. Sorafenib (BAY 43-9006) is a molecular multikinase inhibitor of RAF kinase, platelet-derived growth factor (PDGF), VEGFR-1, -2, -3, platelet-derived growth factor receptor (PDGFR)-β and c-Kit. This molecule inhibits tumor cell proliferation and angiogenesis and it is currently approved for the treatment of hepatocellular carcinoma (HCC).
CASE REPORT
We present the complete remission of resistant psoriasis in a hepatitis C virus (HCV)-infected cirrhotic patient who was treated with sorafenib, for recurrent HCC.
CONCLUSION
Several targeted therapies have demonstrated efficacy against psoriasis. More research and well-designed studies, both in novel drugs and those already marketed for other indications, are needed to determine their value as potential novel therapies for psoriasis.
背景
银屑病是一种慢性、免疫介导且依赖血管生成的疾病。银屑病皮损中活化的角质形成细胞产生促血管生成细胞因子，包括血管内皮生长因子（VEGF），其与血管内皮生长因子受体（VEGFR）结合并促进细胞增殖和血管生成。索拉非尼（BAY 43 - 9006）是一种RAF激酶、血小板衍生生长因子（PDGF）、VEGFR - 1、- 2、- 3、血小板衍生生长因子受体（PDGFR）-β和c - Kit的分子多激酶抑制剂。该分子可抑制肿瘤细胞增殖和血管生成，目前已被批准用于治疗肝细胞癌（HCC）。
病例报告
我们报告了1例丙型肝炎病毒（HCV）感染的肝硬化患者，因复发性HCC接受索拉非尼治疗后，顽固性银屑病完全缓解。
结论
几种靶向治疗已显示出对银屑病有效。需要更多关于新药以及已上市用于其他适应症药物的研究和精心设计的试验，以确定它们作为银屑病潜在新疗法的价值。
Zotero 插件